112 related articles for article (PubMed ID: 35693078)
1. Improved survival with induction chemotherapy and conversion surgery in locally advanced unresectable pancreatic cancer: a single institution experience.
Su YY; Ting YL; Wang CJ; Chao YJ; Liao TK; Su PJ; Chiang NJ; Liao IC; Yu YT; Liu YS; Tsai HM; Li YJ; Huang CJ; Liu IT; Tsai HJ; Yen CJ; Shan YS; Chen LT
Am J Cancer Res; 2022; 12(5):2189-2202. PubMed ID: 35693078
[TBL] [Abstract][Full Text] [Related]
2. A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study.
Su YY; Chiu YF; Li CP; Yang SH; Lin J; Lin SJ; Chang PY; Chiang NJ; Shan YS; Ch'ang HJ; Chen LT
Br J Cancer; 2022 Apr; 126(7):1018-1026. PubMed ID: 34921230
[TBL] [Abstract][Full Text] [Related]
3. Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population.
Li X; Guo C; Li Q; Wei S; Zhang Q; Chen Y; Shen Y; Ma T; Li G; Gao S; Que R; Lou J; Yu R; Yuan Y; Wei Q; Huang P; Liang T; Bai X
Oncologist; 2019 Mar; 24(3):301-e93. PubMed ID: 30459238
[TBL] [Abstract][Full Text] [Related]
4. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.
Hosein PJ; Macintyre J; Kawamura C; Maldonado JC; Ernani V; Loaiza-Bonilla A; Narayanan G; Ribeiro A; Portelance L; Merchan JR; Levi JU; Rocha-Lima CM
BMC Cancer; 2012 May; 12():199. PubMed ID: 22642850
[TBL] [Abstract][Full Text] [Related]
5. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment.
van Roessel S; van Veldhuisen E; Klompmaker S; Janssen QP; Abu Hilal M; Alseidi A; Balduzzi A; Balzano G; Bassi C; Berrevoet F; Bonds M; Busch OR; Butturini G; Del Chiaro M; Conlon KC; Falconi M; Frigerio I; Fusai GK; Gagnière J; Griffin O; Hackert T; Halimi A; Klaiber U; Labori KJ; Malleo G; Marino MV; Mortensen MB; Nikov A; Lesurtel M; Keck T; Kleeff J; Pandé R; Pfeiffer P; Pietrasz D; Roberts KJ; Sa Cunha A; Salvia R; Strobel O; Tarvainen T; Bossuyt PM; van Laarhoven HWM; Wilmink JW; Groot Koerkamp B; Besselink MG;
JAMA Oncol; 2020 Nov; 6(11):1733-1740. PubMed ID: 32910170
[TBL] [Abstract][Full Text] [Related]
7. Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as a second-line treatment regimen for unresectable pancreatic cancer: A real-world analysis.
Tezuka S; Ueno M; Oishi R; Nagashima S; Sano Y; Kawano K; Tanaka S; Fukushima T; Asama H; Konno N; Kobayashi S; Morimoto M; Maeda S
Cancer Med; 2022 Feb; 11(4):1088-1098. PubMed ID: 34953056
[TBL] [Abstract][Full Text] [Related]
8. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial.
Murphy JE; Wo JY; Ryan DP; Clark JW; Jiang W; Yeap BY; Drapek LC; Ly L; Baglini CV; Blaszkowsky LS; Ferrone CR; Parikh AR; Weekes CD; Nipp RD; Kwak EL; Allen JN; Corcoran RB; Ting DT; Faris JE; Zhu AX; Goyal L; Berger DL; Qadan M; Lillemoe KD; Talele N; Jain RK; DeLaney TF; Duda DG; Boucher Y; Fernández-Del Castillo C; Hong TS
JAMA Oncol; 2019 Jul; 5(7):1020-1027. PubMed ID: 31145418
[TBL] [Abstract][Full Text] [Related]
9. Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective Analysis.
Yoo C; Shin SH; Kim KP; Jeong JH; Chang HM; Kang JH; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Park JH; Hwang DW; Song KB; Lee JH; Ryoo BY; Kim SC
Cancers (Basel); 2019 Feb; 11(3):. PubMed ID: 30813624
[TBL] [Abstract][Full Text] [Related]
10. FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study.
Suker M; Nuyttens JJ; Groot Koerkamp B; Eskens FALM; van Eijck CHJ
J Surg Oncol; 2018 Nov; 118(6):1021-1026. PubMed ID: 30259526
[TBL] [Abstract][Full Text] [Related]
11. The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Cancer.
Takada R; Ikezawa K; Daiku K; Maeda S; Abe Y; Urabe M; Kai Y; Yamai T; Fukutake N; Nakabori T; Uehara H; Ashida R; Akita H; Takahashi H; Teshima T; Ohkawa K
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572960
[TBL] [Abstract][Full Text] [Related]
12. A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic Cancer.
Cecchini M; Miccio JA; Pahade J; Lacy J; Salem RR; Johnson SB; Blakaj A; Stein S; Kortmansky JS; Johung KL
Pancreas; 2020 Aug; 49(7):904-911. PubMed ID: 32658074
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.
Barenboim A; Lahat G; Geva R; Nachmany I; Nakache R; Goykhman Y; Brazowski E; Rosen G; Isakov O; Wolf I; Klausner JM; Lubezky N
Eur J Surg Oncol; 2018 Oct; 44(10):1619-1623. PubMed ID: 30146251
[TBL] [Abstract][Full Text] [Related]
14. Nontrial, real-world outcomes in unresectable locally advanced pancreatic cancer: Chemotherapy and chemoradiation is the standard while surgery is uncommon.
Ramaswamy A; Jandyal S; Ostwal V; Engineer R; Lewis S; Bose S; Pande N; Shrikhande SV
Indian J Cancer; 2017; 54(3):530-534. PubMed ID: 29798952
[TBL] [Abstract][Full Text] [Related]
15. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience.
Faris JE; Blaszkowsky LS; McDermott S; Guimaraes AR; Szymonifka J; Huynh MA; Ferrone CR; Wargo JA; Allen JN; Dias LE; Kwak EL; Lillemoe KD; Thayer SP; Murphy JE; Zhu AX; Sahani DV; Wo JY; Clark JW; Fernandez-del Castillo C; Ryan DP; Hong TS
Oncologist; 2013; 18(5):543-8. PubMed ID: 23657686
[TBL] [Abstract][Full Text] [Related]
16. Conversion surgery for an initially unresectable, locally advanced pancreatic cancer after induction chemotherapy and carbon-ion radiotherapy: a case report.
Fujishiro T; Mashiko T; Masuoka Y; Yamada M; Furukawa D; Yazawa N; Kawashima Y; Ogawa M; Hirabayashi K; Nakagohri T
Surg Case Rep; 2018 Sep; 4(1):112. PubMed ID: 30203372
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of FOLFIRINOX-based neoadjuvant therapy for locally advanced pancreatic cancer.
Chen Z; Lv Y; Li H; Diao R; Zhou J; Yu T
Medicine (Baltimore); 2021 Jan; 100(3):e24068. PubMed ID: 33546009
[TBL] [Abstract][Full Text] [Related]
18. Conversion surgery for initially unresectable pancreatic cancer: current status and unresolved issues.
Yoshitomi H; Takano S; Furukawa K; Takayashiki T; Kuboki S; Ohtsuka M
Surg Today; 2019 Nov; 49(11):894-906. PubMed ID: 30949842
[TBL] [Abstract][Full Text] [Related]
19. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
Nitsche U; Wenzel P; Siveke JT; Braren R; Holzapfel K; Schlitter AM; Stöß C; Kong B; Esposito I; Erkan M; Michalski CW; Friess H; Kleeff J
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1212-20. PubMed ID: 26350368
[TBL] [Abstract][Full Text] [Related]
20. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity.
Gunturu KS; Yao X; Cong X; Thumar JR; Hochster HS; Stein SM; Lacy J
Med Oncol; 2013 Mar; 30(1):361. PubMed ID: 23271209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
